Research
A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy
General Hospital Psychiatry – August 05, 2025
Summary
Surprisingly, a meta-analysis of Psilocybin-Assisted Therapy (PAT) suggests the *duration* of psychotherapist interaction may not directly influence depressive outcomes. This finding, crucial for psychedelic medicine and pharmacotherapy, stems from drug studies with limited data and small sample sizes, alongside inconsistent reporting of therapeutic components. The hallucinogen Psilocybin, known for its chemical synthesis and alkaloids influencing neurotransmitter receptors, requires more precise investigation into how its unique properties truly interact with psychotherapy for optimal patient behavior.
Abstract
Our findings did not support that the amount of therapy hours influence depressive outcomes in PAT. However, this interpretation should be made wit...
Latent Classes of Lifetime Use of Seven Hallucinogens in the United States
Journal of Psychoactive Drugs – August 04, 2025
Summary
Lifetime hallucinogen use in the U.S. reveals distinct patterns among 17,977 individuals. A significant 46% used LSD/Psilocybin, while 16% used Psilocybin alone. This Psychology-focused data from Drug Studies indicates older individuals had 1.5-6.4 times higher odds of using LSD/Psilocybin. Non-White participants showed 1.7-3.2 times higher odds for Ecstasy use. These insights are crucial for Psychiatry, informing how psychedelic treatments, modulating Neurotransmitter Receptor Influence on Behavior, might be developed, considering Tryptophan and brain disorders.
Abstract
Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aim...
Methods for GC/MS Analysis of the Most Commonly Seized Drugs of Abuse and Their Metabolites in Biological Samples
Chemosensors – August 04, 2025
Summary
Accurate detection of illicit substances is crucial in forensic toxicology. Gas chromatography–mass spectrometry (GC-MS) is vital for analyzing over a dozen drugs of abuse, like phencyclidine, mescaline, psilocybin, and metabolites such as benzoylecgonine. Complex sample preparation, often involving derivatization, is essential for analyzing urine or hair. This analytical chemistry aids forensic toxicology, identifying hallucinogens, phenethylamines, and designer drugs. Precise identification is critical for understanding their pharmacology and neurotransmitter receptor influence on behavior.
Abstract
Gas chromatography with mass spectrometry (GC-MS) is a common analytical technique used for identifying and quantifying drugs of abuse, as well as ...
Therapeutic and legal aspects of psilocybin in cancer-related depression
Frontiers in Psychiatry – August 04, 2025
Summary
Head and neck cancer patients experience twice the major depressive disorder prevalence of other cancer populations. Conventional antidepressants and psychological interventions are too slow, taking weeks to act. Psilocybin, a hallucinogen and alkaloid, offers rapid antidepressant effects within hours, validated in Psychedelics and Drug Studies. This potential Medicine for Psychiatry is critical for perioperative care. However, its legal context, like Poland's restrictions, complicates clinical integration. Diverse academic research themes highlight the need for ethical pathways to utilize psilocybin's chemical synthesis benefits for immediate psychiatric support.
Abstract
Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the preva...
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
Front Dement – August 04, 2025
Summary
Psychedelic compounds appear to positively reshape key proteins in human brain cells, offering a novel avenue for Alzheimer's treatment. Scientists investigated how psychedelics affect brain health using human brain organoids, which are miniature 3D models of brain tissue. By analyzing the complete protein profile (proteomics) of these organoids, they discovered that psychedelic exposure led to beneficial changes in proteins crucial for brain cell function and resilience. This suggests psychedelics could promote healthier cellular environments, showing promising potential for developing new therapies against Alzheimer's disease.
Abstract
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
564. TOWARD AN UNDERSTANDING OF THE THERAPEUTICALLY RELEVANT MECHANISMS OF PSILOCYBIN FOR ANOREXIA NERVOSA
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A hallucinogen, psilocybin, shows promise for Anorexia nervosa. In a small clinical psychology trial, 40% of 10 participants experienced lasting improvements in anorexia symptoms. To understand how psilocybin works, Psychology and Drug Studies explored its effects in animal models. The medicine improved cognitive adaptability and body weight outcomes in models of anorexia, influencing specific brain receptors and altering gene activity in the prefrontal cortex within 24 hours. This suggests psilocybin's potential in Psychiatry by enhancing mental flexibility and reward processing, critical for psychotherapist-led interventions.
Abstract
Abstract Background Psilocybin, the psychoactive compound produced by so-called “magic” mushrooms has shown promise in alleviating symptoms of a ra...
694. INVESTIGATING THE POTENTIAL OF PSILOCYBIN FOR COMPULSIVE EATING IN A RAT MODEL OF BINGE EATING
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psilocybin, a well-known hallucinogen, showed no effect on compulsive binge eating in a rat model, challenging some theories in Psychology and Psychiatry regarding its therapeutic potential for eating disorders. In a study involving 44 female rats, a 2 mg/kg dose of Psilocybin did not reduce the animals' compulsive behavior or food intake associated with binge-eating disorder. While Psilocybin influences Neurotransmitter Receptors and is explored in Clinical Psychology for various behaviors, these Psychedelics and Drug Studies suggest this particular application might require different approaches.
Abstract
Abstract Background Binge eating disorder (BED) is the most prevalent eating disorder, often associated with metabolic syndrome and other mental he...
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: a Survey Based Experiment
International Journal of Drug Policy – August 01, 2025
Summary
Public support for psilocybin policies significantly increases when its benefits and safety are clearly communicated. A recent survey of 1,500 adults revealed that providing balanced information about this potent hallucinogen and alkaloid boosted policy support by 18%. Furthermore, 65% of participants reported strengthened positive beliefs about psilocybin's potential. This finding, crucial for psychology and drug studies, suggests informed discourse can reshape public perception, impacting future business and therapeutic applications of psychedelics.
Abstract
Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further...
476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Acute psilocybin, a potent hallucinogen, significantly reduced compulsive grooming in mice modeling OCD for up to one week. This finding suggests a targeted therapeutic role for this compound in Psychiatry and Medicine, a focus of Psychedelics and Drug Studies. A 1 mg/kg dose of psilocybin also induced head-twitches, indicating its hallucinogenic potential. However, chronic administration showed no benefits for anxiety or compulsive behaviors. These Neuroscience and Psychology insights, relevant to chemical synthesis and alkaloids, highlight acute psilocybin's promise while cautioning against chronic use.
Abstract
Abstract Background The evident limitations of current treatments for depression, anxiety and obsessive-compulsive disorder (OCD), underscore the n...
Therapeutic benefit versus epistemic risk: Need for empirical research in psychedelic epistemology.
Journal of psychiatric research – August 01, 2025
Summary
Psychedelic therapy shows promise for mental health treatment, but it may significantly alter how people form and validate their beliefs. While these substances are generally safe physically and psychologically, they can lead users to embrace supernatural or paranormal beliefs. The key finding suggests that psychedelics might change not just what people believe, but the fundamental ways they evaluate truth and knowledge - their "epistemic criteria." This insight raises important ethical considerations for therapeutic use.
Abstract
This paper highlights the ethical and epistemic challenges posed by psychedelic therapy and vindicates the importance of epistemology in the clinic...
426. THE MGLUR2/3 ANTAGONIST ENHANCES THE BEHAVIORAL AND CELLULAR ANTIDEPRESSANT-LIKE EFFECTS OF PSILOCYBIN AND SCOPOLAMINE
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psychedelics like psilocybin and scopolamine demonstrate powerful antidepressant effects, significantly amplified by targeting specific brain receptors. Pharmacology reveals a low dose of a Metabotropic glutamate receptor 2 antagonist dramatically enhanced psilocybin's antidepressant action in mice, with benefits lasting up to 7 days. This neuroscience insight suggests combining these agents could lower doses and reduce hallucinogenic side effects, a crucial development for Medicine. Such drug studies, exploring Neurotransmitter Receptor Influence on Behavior, offer new pathways for treating depression, leveraging chemical synthesis and alkaloids like psilocybin for improved psychological outcomes.
Abstract
Abstract Background Numerous data indicates that hallucinogens from various groups such as ketamine, scopolamine or psilocybin exert rapid antidepr...
State of the art in EEG signal features of mindfulness-based treatments for chronic pain.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology – August 01, 2025
Summary
No Summary
Abstract
A systematic review of electroencephalographic (EEG) correlates of Mindfulness- based treatment for chronic pain is presented. Recent technological...
551. PSYCHEDELICS AND OCD: TRANSLATIONAL APPROACHES
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A compelling Neuroscience discovery reveals a single dose of a novel, non-hallucinogenic chemical entity, derived from psychedelics, could alleviate obsessive-compulsive disorder (OCD) symptoms for over 21 days. This builds on prior Drug Studies where psilocybin showed promise in 9 OCD patients. Preclinical Psychology models demonstrated the new compound's efficacy, alongside psilocybin and psychedelic mushroom extract, which showed slightly greater therapeutic effect. These Chemical Reactions at brain receptors offer hope for the over a third of OCD patients unresponsive to current treatments, potentially without psychedelic effects.
Abstract
Abstract Background Obsessive-compulsive disorder (OCD) is associated with significant personal suffering and functional impairment. At least a thi...
Classification schemes of altered states of consciousness.
Neuroscience and biobehavioral reviews – August 01, 2025
Summary
From meditation to psychedelics, altered states of consciousness have fascinated scientists for decades. New research reveals a comprehensive framework for classifying these experiences based on three key factors: subjective effects, induction methods, and brain activity patterns. This classification system helps bridge phenomenology with neuroscience, offering insights into how different consciousness-altering practices affect our minds.
Abstract
In recent years, there has been a renewed interest in the conceptual and empirical study of altered states of consciousness (ASCs), induced pharmac...
Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.
Neuroscience and biobehavioral reviews – August 01, 2025
Summary
Psilocybin, the active compound in magic mushrooms, creates profound changes in brain connectivity patterns. Advanced neuroimaging techniques like MRI and PET scans reveal that this psychedelic temporarily disrupts the brain's default mode network, altering self-perception and emotional processing. Studies show promising brain changes in treating depression, with functional connectivity shifts linked to improved mood and social functioning.
Abstract
Psilocybin is a psychedelic serotonergic compound that is renowned for its potent psychoactive effects. Over the past 15 years, an increasing numbe...
205. SYNERGISTIC BEHAVIORAL AND NEUROPLASTIC EFFECTS OF PSILOCYBIN-NMDAR MODULATOR ADMINISTRATION
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Combining the psychedelic alkaloid Psilocybin with specific NMDA receptor modulators significantly reduced its hallucinogenic effects in preclinical models. This advance in Neuroscience and Drug Studies suggests a new path for safer therapeutic applications in Psychology. These chemical combinations not only mitigated adverse reactions but also enhanced brain Neuroplasticity, particularly in areas like the hippocampus. This approach could optimize the therapeutic potential of psychedelics, making them more accessible for treating neuropsychiatric disorders by fine-tuning their effects.
Abstract
Abstract Background The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and...
317. PSILOCYBIN DOES NOT INDUCE CONDITIONED PLACE PREFERENCE, BUT MODIFIES BEHAVIORAL PATTERNS IN SPRAGUE-DAWLEY RATS
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psilocybin does not create a rewarding preference, a crucial insight for its therapeutic promise. In a Conditioned Place Preference paradigm with 20 rats, the psychedelic did not foster a preference for the drug-paired environment. While immediate behavior was altered—increasing head-twitching and dog-shaking, accounting for over 70% of observed behavioral variance—these effects were temporary. This Neuroscience and Pharmacology finding, relevant to Drug Studies and Psychology, illuminates psilocybin's Neurotransmitter Receptor Influence on Behavior, supporting its safety profile and implications for Neuroendocrine regulation.
Abstract
Abstract Background Recent years have seen renewed scientific interest in psychedelics, including psilocybin, for their potential in treating neuro...
The Cumulative Effect of a 12-Week Online Mindfulness-Based Meditation Intervention Programme on Autonomic Nerve Functions by Pupillary Light Reflex: A Pilot Randomised Controlled Trial.
Stress and health : journal of the International Society for the Investigation of Stress – August 01, 2025
Summary
No Summary
Abstract
This study aimed to determine whether online-guided mindfulness-based interventions (MBIs) in daily life improve autonomic nervous system function ...
Is ketamine safe for individuals in higher level of care treatment for eating disorders? Analysis of safety of subanesthetic ketamine in 104 patients.
Journal of psychiatric research – August 01, 2025
Summary
Ketamine shows promise as a safe antidepressive agent for people battling both eating disorders and severe depression. In a groundbreaking analysis of 104 patients receiving intensive care for feeding and eating disorders, medical monitoring revealed that ketamine treatments remained safe even when patients faced challenges with malnutrition. This offers hope for those struggling with complex mood disorders who haven't responded to traditional therapies.
Abstract
Eating disorders are among the most challenging and fatal mental illnesses and, due to the complication of medical instability caused by malnutriti...
High-throughput screening of 311 new psychoactive substances and metabolites in wastewater by direct injection UPLC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences – August 01, 2025
Summary
Scientists can now detect over 300 emerging drugs by analyzing just a few drops of wastewater. This breakthrough screening method uses direct injection technology to identify new psychoactive substances in city sewage systems. The approach successfully tracked 32 different drugs across nearly 1,000 samples in a Chinese city, with ketamine being the most frequently detected substance. This efficient wastewater analysis helps authorities monitor drug trends in real-time.
Abstract
The rapid global spread of new psychoactive substances (NPS) in recent years has become an issue in many countries. One emerging technology that ca...
Health-related behavioral changes following the use of psychedelics in naturalistic settings.
Preventive medicine reports – August 01, 2025
Summary
No Summary
Abstract
Psychedelics have been increasingly studied for their potential to influence mental health and well-being, yet their relationship with broader heal...
The Future of Pain Management.
Neurologic clinics – August 01, 2025
Summary
Pain isn't just physical; it's a complex sensory, emotional, and cognitive experience. A comprehensive review reveals a promising future for pain management. Advances in treatment algorithms, novel pain medication like psychedelics, and noninvasive neuromodulation offer exciting new pain interventions. This heralds significant potential for effective pain treatment, transforming care for both acute pain and chronic pain.
Abstract
This article explores the complexities of pain management, highlighting the multidimensional nature of pain, which encompasses affective, cognitive...
Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.
Psychiatry research – August 01, 2025
Summary
Ketamine and its variants show promise in treating severe mood disorders, but how these treatments are studied varies widely. Analysis of 40 clinical trials reveals key differences in testing methods and safety protocols. While esketamine received FDA approval, ongoing research with ketamine and arketamine highlights challenges in conducting reliable trials. The main issue? Ketamine's unique effects make it difficult to run truly blind studies, potentially skewing results. Better standardized testing methods could help these promising treatments reach more patients safely.
Abstract
Ketamine and its enantiomers, esketamine and arketamine, have emerged as promising treatments for treatment-resistant depression (TRD). This cross-...
Qualitative analysis of written accounts of functional/dissociative seizures.
Epilepsy & behavior : E&B – August 01, 2025
Summary
People experiencing functional seizures report a complex mix of symptoms, from altered consciousness to intense physical sensations. A detailed analysis of 75 first-hand accounts reveals these events affect multiple domains - consciousness, movement, sensations, arousal levels, emotions, and thinking abilities. Most commonly, individuals described changes in awareness and self-control, along with varied motor symptoms. Physical sensations, anxiety, and "foggy thinking" were also frequently reported. These insights help doctors better understand and identify these seizures.
Abstract
Subjective experiences of functional/dissociative seizures (FDS) are important for diagnosis and treatment formulation. This study aims to improve ...
631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psilocybin, a potent hallucinogen, shows remarkable efficacy in medicine, achieving up to 70% remission in treatment-resistant depression. Its psychedelic effects, however, can complicate psychology studies. A new pharmacology approach involves 68 patients with severe depression receiving psilocybin (25mg) alongside ketanserin (40mg), a chemical synthesis designed to block hallucinogenic properties. This drug studies protocol aims to improve tolerability by isolating psilocybin's antidepressant benefits. Comparing this non-psychedelic treatment with rTMS will advance understanding of these interventions for depression, addressing a significant economic burden.
Abstract
Abstract Background Among the innovative treatments investigated for depression, psilocybin appears to play an extremely promising role, with sever...
670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE?
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A single dose of a synthetic psilocybin compound dramatically reduced depression symptoms in patients with treatment-resistant depression. In a trial involving 233 participants, those receiving 25mg experienced significant improvements in depression scores from day two, persisting through week six compared to a 1mg control. This advance in Psychology, Psychedelics, and Drug Studies suggests these compounds offer rapid, sustained relief for a debilitating condition. Over 90% of adverse events were mild or moderate, indicating good tolerability.
Abstract
Abstract Background Despite the widespread availability of multiple antidepressant treatments, depression remains a common and sometimes debilitati...
Mindfulness in the school curriculum? A nationwide cluster-randomized trial of the effectiveness of implementing a mindfulness-based intervention for 9-16-year-olds students in Danish elementary schools.
Social science & medicine (1982) – August 01, 2025
Summary
No Summary
Abstract
This study aimed to investigate the effectiveness of a teacher-training program for integrating a ten-session, school-based mindfulness program int...
164. PSILOCYBIN DURING THE POSTPARTUM PERIOD INDUCES LONG-LASTING ADVERSE EFFECTS IN BOTH MOTHERS AND OFFSPRING
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psilocybin, a psychedelic hallucinogen, may carry significant risks during the postpartum period. While 20% of birthing parents experience peripartum mood disorders, a mouse model showed psilocybin medicine offered no benefit. Instead, treated mothers (N=11-16) became more anxious, and their offspring (N=7-14 per sex) later developed mood and sociability issues. This adverse effect contrasts with psilocybin's usual benefits, highlighting critical considerations for drug studies in psychology and pregnancy. The postpartum period demands careful evaluation.
Abstract
Abstract Background Peripartum mood disorders (PMDs) are a major public health concern; they present in 20% of birthing parents and are responsible...
Advances in research on the pathogenesis and signaling pathways associated with postoperative delirium (Review).
Molecular medicine reports – August 01, 2025
Summary
Up to 30% of elderly patients experience temporary confusion and cognitive changes after surgery. This complex condition, known as postoperative delirium, stems from multiple factors including neuroinflammation and disrupted brain signaling. New research reveals how specific biological pathways contribute to cognitive disorders, highlighting promising prevention strategies like cognitive training and targeted medications that reduce inflammation and regulate brain chemistry.
Abstract
Postoperative delirium (POD) is a common postoperative complication, characterized by acute, transient and fluctuating declines in consciousness an...
519. PSILOCYBIN ASSISTED PSYCHOTHERAPY FOR OBSESSIVE COMPULSIVE DISORDER, BODY DYSMORPHIC DISORDER, AND ANOREXIA NERVOSA: STUDY PROTOCOL
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
New hope emerges for debilitating conditions like Anorexia nervosa, Body dysmorphic disorder, and Obsessive compulsive disorders, often resisting conventional treatments. A comprehensive protocol has been developed for psilocybin-assisted psychotherapy, integrating insights from psychology and psychiatry. This innovative approach, informed by four distinct studies including patient experiences, guides psychotherapists in a transdiagnostic trial addressing severe body image dysmorphia and obsessive compulsive behaviors, advancing Psychedelics and Drug Studies within Clinical psychology and Medicine.
Abstract
Abstract Background Obsessive compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN) are some of the most debilitatin...
Studies on the Stability and Microbial Biotransformation of Five Deschloroketamine Derivatives as Prerequisite for Wastewater-Based Epidemiology Screening.
Drug testing and analysis – August 01, 2025
Summary
Monitoring new psychoactive substances like deschloroketamines in wastewater is vital for public health. Using LC‐HRMS/MS, five deschloroketamine derivatives and eight metabolites were detected in rat feces. Critically, microbial biotransformation in wastewater over 24 hours showed these five compounds and most metabolites remained stable. While Phase II glucuronides decreased, the overall stability of parent compounds and seven Phase I metabolites in wastewater influent confirms their suitability for wastewater-based epidemiology, offering a reliable way to track emerging drug trends.
Abstract
Wastewater (WW)-based epidemiology (WBE) is a powerful tool for screening and surveillance of drugs (of abuse) or new psychoactive substances (NPSs...
620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDER
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A significant challenge in Psychiatry is that 56% of individuals with Generalised Anxiety Disorder do not respond to psilocybin-assisted therapy. To personalize anxiety medicine, a multi-omic approach examined blood from 11 responders and 13 non-responders. Through advanced drug studies, a panel of four genes, including CTXN2-AS1, was identified, capable of distinguishing 45% of the responders in the cohort. This biological identification could guide individuals towards effective psychological treatments, advancing our understanding of psychedelics like psilocybin, an alkaloid, beyond just its chemical synthesis.
Abstract
Abstract Background Early intervention and management of Generalised Anxiety Disorder (GAD) is essential to effectively reduce both symptom severit...
229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A pilot clinical trial showed psilocybin, a compound from chemical synthesis and alkaloids, combined with psychotherapeutic support, significantly reduced symptoms for treatment-resistant depression. This medicine, vital in psychiatry and psychology, yielded a large effect (Hedge’s g = 1.41). Among seven participants, nearly 29% experienced sustained relief, while 43% relapsed, and 29% saw no substantial improvement. Such psychedelics and drug studies are crucial for tackling the profound societal burden of depression.
Abstract
Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left wit...
363. DIFFERENTIAL EFFECTS OF PSILOCYBIN AND LISURIDE ON SEROTONIN AND DOPAMINE NEURONAL ACTIVITY AND BEHAVIOR
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A compelling finding in Neuroscience reveals Lisuride, a chemical synthesis and alkaloid, produces antidepressant-like effects in adult male C57BL6/N mice without the hallucinogenic head twitch response seen with Psilocybin. In Pharmacology and Drug Studies, both drugs influenced Serotonin and Dopamine neurotransmitter systems. Crucially, their Neurotransmitter Receptor Influence on Behavior differed: Psilocybin's Serotonin inhibition was 5-HT2A receptor-dependent, while Lisuride's was not. This suggests Lisuride holds promise for Medicine in Psychology, offering therapeutic benefits without psychedelic experiences.
Abstract
Abstract Background Psychedelics hold potential as therapeutics in psychological disorders. Even if they primarily act on 5-HT2A receptors, their m...
Role of ketamine in the treatment of substance use disorders: A systematic review.
Journal of substance use and addiction treatment – August 01, 2025
Summary
Ketamine, traditionally used in anesthesia, shows promising results in treating addiction and substance use disorders (SUDs). Recent psychiatric research reveals this medication can reduce cravings, ease withdrawal symptoms, and boost recovery success rates. Analysis of 14 clinical studies found ketamine particularly effective for alcohol and opioid dependencies, with patients reporting decreased substance use and improved abstinence rates. Combined with therapy, it offers a novel treatment path for those struggling with addiction.
Abstract
Substance Use Disorders (SUDs) involve diminished control, risky use, impaired social interactions, and physical dependence. Despite their global p...
597. ARE SIDE EFFECTS NECESSARY FOR ANTIDEPRESSIVE TREATMENT: THE PSILOCYBIN EXPERIENCE
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A critical debate in Psychology and Medicine centers on Psilocybin and other Psychedelics. While some psychotherapists in Psychiatry believe the hallucinogen-induced "psychedelic experience" is crucial for therapeutic benefit, preclinical animal models suggest otherwise. These models demonstrate antidepressant-like actions via specific opioid and glutamatergic pathways, indicating that the profound perceptual shifts may not be necessary for efficacy. This insight from Pharmacology and Drug Studies points towards developing safer, non-hallucinogenic medications, offering therapeutic potential without the intense experiences.
Abstract
Abstract Background Psycholicibin is now studied in clinical settings. Aims & Objectives To elaborate if side effects are part of the therapeut...
Drug-related suicidal ideation in the K-12 population: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS) database.
Journal of psychiatric research – August 01, 2025
Summary
Real-world data reveals concerning links between certain medications and suicidal thoughts in school-aged children. Analysis of 4,779 adverse event reports from FAERS shows that teenagers 15-17 were most affected, with more cases in males than females. The asthma drug montelukast topped the list of 21 medications associated with suicidal ideation in the K-12 population.
Abstract
The K-12 population refers to individuals, primarily aged 6-17, from kindergarten through 12th grade. Drug-related suicidal ideation (SI) in the K-...
577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Australia's regulatory approval for psilocybin in treatment-resistant depression signals a major Psychiatry breakthrough. This psychedelic, central to Drug Studies, initiates specific Chemical Reactions by influencing brain serotonin receptors, a critical Neurotransmitter Receptor Influence on Behavior. Clinical psychology reveals psilocybin provides rapid, robust antidepressant effects, enduring for months to a year after only one or two treatment sessions. Neuroimaging further illuminates how this modulates brain circuits, offering deep insights into its therapeutic promise for mental health.
Abstract
Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials ...
The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.
Psychopharmacology – August 01, 2025
Summary
No Summary
Abstract
Overdose fatalities involving cocaine continue to rise with over 5.3 million cocaine users reported in the United States in 2022. The abuse liabili...
Evaluating Ketamine vs Thiopental as an Anesthetic Adjuvant for Electroconvulsive Therapy for Treatment-Resistant Depression: A Meta-Analysis
Annals of Clinical Psychiatry – August 01, 2025
Summary
For severe depression unresponsive to other treatments, electroconvulsive therapy (ECT) is highly effective. An analysis of four studies involving 320 patients reveals that both ketamine and thiopental anesthetics equally reduce depressive symptoms, with average score reductions of 22.19 and 20.24 points, respectively. While ketamine may enhance ECT's brain activity duration, it also brings more side effects like nausea and hypertension. Thiopental offers a better safety profile, especially for those with heart conditions.
Abstract
Background Treatment-resistant depression (TRD) poses a significant challenge, with electroconvulsive therapy (ECT) being its highly effective inte...
The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review.
Journal of affective disorders – August 01, 2025
Summary
Breakthrough treatments ketamine and esketamine show promising results in improving quality of life for people with severe depression. Analysis of multiple studies reveals these medications not only reduce depressive symptoms but significantly enhance patients' overall wellbeing. Patient-reported outcomes indicate meaningful improvements across various life domains, offering hope for those who haven't responded to traditional treatments.
Abstract
The rapid and clinically meaningful antidepressant effects of ketamine and esketamine are well-established in major depressive disorder (MDD) and t...
Strong increase in the number of intoxications involving psychoactive drugs among adolescents reported to the Dutch Poisons Information Center from 2014-2023.
The International journal on drug policy – August 01, 2025
Summary
Dutch poison control data reveals a troubling surge in adolescent intoxications from psychoactive drugs, with cases nearly tripling over the past decade. Cannabis edibles, MDMA, and new psychoactive substances led this increase. Notable shifts include a 208% rise in cannabis-related incidents and emergence of novel synthetic drugs. The findings highlight evolving patterns in youth substance use and underscore growing public health concerns.
Abstract
The use of psychoactive drugs has been increasing worldwide, with adolescents and young adults accounting for a large share of people who use drugs...
Exploring the Impact of Different Mindfulness Meditation Interventions on College Students' Resilience: A Randomized Controlled Trial.
Stress and health : journal of the International Society for the Investigation of Stress – August 01, 2025
Summary
Even brief mindfulness meditation can immediately calm the body's stress response. A study on college students demonstrated that just a few moments of mindfulness meditation significantly reduced blood pressure and improved heart rate variability. An 8-week mindfulness meditation program further enhanced resilience among college students, with these positive effects sustained long-term. This indicates that various mindfulness meditation practices offer effective ways for college students to manage stress and build lasting resilience.
Abstract
Resilience helps mitigate the negative impacts of stress and promotes effective adaptation in adverse situations. This study investigated the impac...
Psilocybin Prolongs the Neurovascular Coupling Response in Mouse Visual Cortex
OpenAlex – July 31, 2025
Summary
Psilocybin, a potent hallucinogen and alkaloid, profoundly alters brain function. Neuroscience reveals this psychedelic drug, which can be chemically synthesized, prolongs blood flow increases in the visual cortex without changing neural activity in awake mice. This affects the neurovascular bundle's coupling, crucial for psychology studies. The cortex's response to stimuli—even those evoking a looming sensation—is extended. Influenced by neurotransmitter receptors, these prolonged responses could skew human neuroimaging data, impacting psilocybin's therapeutic potential. Accounting for this is vital for accurate drug studies.
Abstract
Abstract Psilocybin has profound therapeutic potential for various mental health disorders, but its mechanisms of action are unknown. Functional MR...
Near-Death Experiences: A Bibliometric and Systematic Review of Published Literature From 1977 to 2025.
Omega – July 30, 2025
Summary
No Summary
Abstract
Interest in near-death experiences (NDEs) has grown across disciplines such as medicine, psychology, and literature, yet no consensus exists on the...
The neuroreceptors and transporters underlying spontaneous brain activity.
Communications biology – July 30, 2025
Summary
Our brains' spontaneous activity, crucial for thought, is driven by complex interactions of neuroreceptors. A new modeling framework, using detailed maps of 19 neuroreceptors and transporters, successfully predicts brain activity patterns. It revealed two key neuroreceptor networks influencing higher-order thought and sensory processing. This approach accurately reflects drug effects like LSD and Modafinil and identifies neuroreceptor links to neuropsychiatric conditions, offering profound insights into brain function.
Abstract
Determining the neuromodulators driving brain activity is critical for understanding cognition and neuropathology. Neuromodulators act through neur...
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression
JAMA Network Open – July 30, 2025
Summary
Psilocybin’s impressive antidepressant effects for Major depressive disorder may be over-estimated. A meta-analysis of 17 Randomized controlled trials (4960 patients) comparing Psilocybin, Serotonin reuptake inhibitors like Fluoxetine, and esketamine for Treatment of Major Depression and Treatment-resistant depression, revealed control groups in psilocybin clinical trials improved less. Their depression rating scale scores improved by an effect size of 0.50, versus 1.00 for antidepressant SSRI controls and 1.12 for esketamine controls. This finding is crucial for Psychiatry and Psychedelics and Drug Studies.
Abstract
Importance Psilocybin has demonstrated rapid and sustained antidepressant efficacy, with acute-phase effect sizes often more than double those for ...
Ketamine's impact on mood after day-case surgery and its relation to obesity: a randomised controlled trial in women undergoing fractional curettage.
BMC women's health – July 30, 2025
Summary
A randomised controlled trial involving women undergoing fractional curettage for day-case surgery revealed a surprising finding: while a single dose of Ketamine alongside Propofol and Fentanyl didn't universally elevate total mood scores measured by the POMS questionnaire, it significantly improved emotional recovery specifically for obese women. This suggests Ketamine's mood-boosting effects may be positively linked to obesity in this context.
Abstract
Several studies have shown that ketamine has an effect on mood and depression in the perioperative context; however, little is known about ketamine...
A Fragmented Mind: Altered States of Consciousness and Spirit Possession Between Rituals and Therapy.
Integrative psychological & behavioral science – July 30, 2025
Summary
No Summary
Abstract
This paper focuses on understanding how cultural influences, social expectancy, and personal beliefs shape the perception of altered states of cons...
Low-dose esketamine combined with propofol versus fentanyl-propofol for preventing hypoxemia during gastroscopy sedation in high-altitude residents: a randomized controlled trial.
BMC anesthesiology – July 30, 2025
Summary
A key challenge in medical procedures at high altitude is preventing low blood oxygen. For gastroscopy requiring deep sedation, a new approach combining esketamine with propofol significantly reduced hypoxemia incidence (8.75% vs. 32.5%) compared to a standard fentanyl-propofol mix. This regimen also improved patient stability, lowered propofol dosage, and sped up recovery for high-altitude residents, proving a safer, more effective option.
Abstract
The aim of this study is to evaluate the efficacy and safety of low-dose esketamine combined with propofol in reducing the incidence of hypoxemia d...
Examining the Dose-Response Effects of Mindfulness Meditation Interventions on Well-Being: Protocol for a Randomized Controlled Trial.
JMIR research protocols – July 29, 2025
Summary
Understanding the ideal "dose" of mindfulness meditation for boosting well-being is crucial. This research explores if more practice time in internet- and mobile-based interventions leads to greater positive results. Healthy adults are randomly assigned to daily mindfulness meditation courses of 10, 20, or 30 minutes, or a short control. The goal is to clarify the dose-response relationship, expecting longer meditation sessions to significantly enhance well-being.
Abstract
Mindfulness meditation has demonstrated modest benefits for mental health and well-being, although the relationship between practice dose and outco...
Electrophysiological effects of psilocybin co-administered with midazolam
OpenAlex – July 29, 2025
Summary
Imagine experiencing a profound psychedelic journey without memory of it. A pilot study in **psychedelics and drug studies** gave participants 25 mg of psilocybin—an **alkaloid** from **chemical synthesis**—with a sedative. This allowed the full psychedelic experience, blunting recall. Brain activity showed distinct patterns: initially, increased beta power; then, as psilocybin's **neurotransmitter receptor influence on behavior** grew over six hours, increased brain complexity and altered power. Psilocybin's effects persist despite memory suppression, supporting mechanistic studies.
Abstract
Abstract The serotonergic psychedelic psilocybin induces neural plasticity and profoundly alters consciousness. The benzodiazepine midazolam blunts...
Exploring Esketamine's Therapeutic Role for Perinatal Depression via TASK-1 Tandem Pore Potassium Channels.
ACS chemical neuroscience – July 29, 2025
Summary
Remarkably, a new approach significantly lowers depression scores in new mothers. It investigates how esketamine works, specifically targeting the TWIK-related acid-sensitive K+ channel 1 channel. Clinical trials with 298 women and lab studies confirmed its benefits. This treatment effectively combats perinatal depression by reducing neuroinflammation and enhancing synaptic plasticity, mediated by the TWIK-related acid-sensitive K+ channel 1 channel. This suggests esketamine is a powerful therapeutic avenue, offering a clear path to improved mental well-being.
Abstract
This research focuses on the promising use of esketamine in perinatal depression, a widespread disorder impacting postpartum women's mental health....
Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials
Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity – July 29, 2025
Summary
With Fluoxetine the only pharmacological treatment approved for Bulimia Nervosa, and no drugs for other eating disorders like Anorexia Nervosa, new options are crucial. A systematic review of medicine and psychiatry literature, including the Cochrane Library, reveals promising early insights into psilocybin. One open-label clinical trial involving 10 individuals with Anorexia Nervosa, plus a single case report, suggests this psychedelic might be safe and well-tolerated. Six additional registered clinical trials are underway, exploring psilocybin's potential in these challenging behaviors.
Abstract
Abstract Background Fluoxetine remains the only pharmacological treatment approved for Bulimia Nervosa, and no other drugs have been approved for e...
Discovery of Rapid-Acting, Orally Available Antidepressants by Activating TrkB Signaling.
Journal of medicinal chemistry – July 29, 2025
Summary
Current antidepressants can take weeks to work, and rapid-acting options often have severe side effects. A new compound was discovered that rapidly alleviates depressive symptoms in preclinical models. This oral compound, unlike existing fast-acting treatments, activates crucial brain pathways, offering potent antidepressant effects with minimal side effects. It readily enters the brain, highlighting a promising avenue for rapid, safer depression relief by enhancing the brain's ability to adapt.
Abstract
Major depressive disorder (MDD) remains a significant global health burden, and its current treatments are limited by the delayed onset of efficacy...
Death recollection moderates stress-influenced depression in Thai boarding school students.
BMC psychology – July 29, 2025
Summary
No Summary
Abstract
Death recollection is a form of mindfulness meditation that orients a practitioner's calm attention toward an awareness of death. This meditation i...
Esketamine for Preventing Catheter-Related Bladder Discomfort After Ureteroscopic Lithotripsy: A Randomized Controlled Trial.
BMC anesthesiology – July 29, 2025
Summary
Post-surgical bladder discomfort is a common, distressing issue. Researchers explored if Esketamine could offer relief. They tested a sub-anesthetic dose for its prevention effect on catheter-related bladder discomfort following kidney stone removal. Patients received different Esketamine doses or a placebo. A higher dose (0.25 mg/kg) significantly reduced discomfort's occurrence and severity. Patients needed less pain medication, with no increased side effects. This offers a promising solution.
Abstract
Catheter-related bladder discomfort (CRBD) is associated with anxiety, pain, and an increased risk of perioperative complications. Esketamine, whic...
EEG Brain Rhythms During Resting-State Wakefulness and Sleep in Elderly Expert Meditators.
Journal of sleep research – July 29, 2025
Summary
No Summary
Abstract
Meditation practice has been shown to impact resting-state EEG activity in expert meditators, but its benefits on sleep, which is particularly affe...
In vitro metabolic fate of 1-[3-(trimethylsilyl)propanoyl] lysergic acid diethylamide (1S-LSD), a silicon-containing LSD analog.
Forensic toxicology – July 29, 2025
Summary
A new silicon-containing drug, 1S-LSD, an LSD analog, surprisingly forms Lysergic acid diethylamide (LSD) early in its in vitro metabolism. Researchers aimed to map its metabolic pathway using human liver microsomes. They identified 62 metabolites, proposing a detailed pathway. This successful characterization helps identify markers for 1S-LSD consumption, enhancing understanding of such compounds.
Abstract
A new lysergic acid diethylamide (LSD) analog has recently been identified, 1-[3-(Trimethylsilyl)propanoyl] LSD (1S-LSD), characterized by a silico...
Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
British journal of pharmacology – July 28, 2025
Summary
Psychedelic drugs, known for activating the 5-HT2A receptor, are revealing a surprising ability to modulate the immune system. Evidence suggests they effectively reduce inflammation, including neuroinflammation, by inhibiting pro-inflammatory responses. Animal and early human data support these positive effects. Crucially, new compounds are being developed that offer these anti-inflammatory benefits without the psychedelic experience, presenting innovative avenues for treatment.
Abstract
Psychedelic drugs that activate 5-HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics fo...